A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 193,768 shares of TBPH stock, worth $1.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
193,768
Previous 177,612 9.1%
Holding current value
$1.7 Million
Previous $1.59 Million 3.14%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$8.29 - $9.92 $133,933 - $160,267
16,156 Added 9.1%
193,768 $1.64 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $11.59 $1.38 Million - $1.94 Million
167,529 Added 1661.5%
177,612 $1.59 Million
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $837,965 - $1.11 Million
-97,665 Reduced 90.64%
10,083 $113,000
Q3 2023

Nov 15, 2023

SELL
$8.38 - $10.44 $116,632 - $145,303
-13,918 Reduced 11.44%
107,748 $929,000
Q2 2023

Aug 14, 2023

BUY
$10.16 - $11.92 $132,394 - $155,329
13,031 Added 12.0%
121,666 $1.26 Million
Q1 2023

May 15, 2023

BUY
$9.87 - $11.44 $150,033 - $173,899
15,201 Added 16.27%
108,635 $1.18 Million
Q4 2022

Feb 14, 2023

BUY
$9.65 - $11.34 $901,638 - $1.06 Million
93,434 New
93,434 $1.05 Million
Q2 2022

Aug 15, 2022

BUY
$8.41 - $10.34 $600,171 - $737,903
71,364 Added 223.6%
103,280 $936,000
Q1 2022

May 16, 2022

SELL
$8.33 - $12.96 $1.18 Million - $1.83 Million
-141,498 Reduced 81.6%
31,916 $305,000
Q4 2021

Feb 14, 2022

BUY
$7.42 - $11.05 $903,051 - $1.34 Million
121,705 Added 235.37%
173,414 $1.92 Million
Q3 2021

Nov 15, 2021

BUY
$6.77 - $14.41 $350,069 - $745,126
51,709 New
51,709 $383,000

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $586M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track Paul Tudor Jones's Portfolio

Track Paul Tudor Jones Portfolio

Follow Paul Tudor Jones (Tudor Investment Corp Et Al) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.